​Specifications for the Usage and Dosage of Anagrelide

Release date: 2026-03-27 16:08:44     Recommended: 3

As a specialized platelet-lowering medication, Anagrelide also plays an important role in the clinical management of secondary thrombocythemia.

I. Specifications for Anagrelide Usage and Dosage

1. Dosage for Adult Patients

(1) The recommended starting dose is 2 mg per day, administered via one of two regimens: 0.5 mg four times daily or 1 mg twice daily.

(2) Maintain the starting dose for at least one week before making dosage adjustments.

2. Dosage for Pediatric Patients

(1) For children aged 7 years and above, the recommended starting dose is 0.5 mg per day.

(2) The safety of use in children under 6 years of age has not been established; use should be avoided.

3. Principles of Dosage Adjustment

(1) Dose escalation should not exceed 0.5 mg/day per week. The single dose should not exceed 2.5 mg, and the total daily dose should not exceed 10 mg.

(2) For most patients, a maintenance dose within the range of 1.5–3.0 mg per day is sufficient to achieve a satisfactory therapeutic effect.

4. Dosage for Patients with Hepatic Impairment

(1) For patients with moderate hepatic impairment, treatment should be initiated at a dose of 0.5 mg per day, with close monitoring for cardiovascular events.

(2) Anagrelide should be avoided in patients with severe hepatic impairment.

II. Important Safety Considerations for Anagrelide

1. Cardiovascular Toxicity Monitoring

(1) Anagrelide can cause QT interval prolongation and ventricular tachycardia.

(2) All patients should undergo a comprehensive cardiovascular assessment, including an electrocardiogram, prior to treatment.

(3) Continuous monitoring for cardiovascular effects is required during treatment.

2. Bleeding Risk Management

(1) The concomitant use of Anagrelide and aspirin increases the risk of major bleeding events.

(2) The potential risks and benefits of concomitant use should be evaluated, particularly in patients with characteristics that increase bleeding risk.

3. Pulmonary Hypertension Assessment

(1) Pre-existing cardiopulmonary disease should be assessed prior to treatment.

(2) If symptoms such as dyspnea, leg swelling, or cyanosis of the lips and skin develop, immediate medical attention should be sought.

4. Drug Interaction Management

(1) Avoid concomitant use with medications that prolong the QT interval, including chloroquine, clarithromycin, haloperidol, and others.

(2) As Anagrelide is a phosphodiesterase 3 inhibitor, concomitant use of drugs with similar properties should be avoided.

III. Healthy Lifestyle Recommendations for Patients Taking Anagrelide

1. Daily Activity Management

(1) Adverse reactions such as headache, palpitations, diarrhea, and asthenia may occur during the initial treatment period. It is recommended to plan daily activities accordingly and avoid overexertion.

(2) As the patient gradually acclimates to the medication, normal activity levels can be progressively resumed.

2. Dietary Management Recommendations

(1) Anagrelide and its active metabolite are primarily metabolized by CYP1A2.

(2) Patients taking CYP1A2 inducers may require dose adjustments to compensate for reduced Anagrelide exposure.

3. Key Points for Symptom Monitoring

(1) Closely monitor for symptoms such as palpitations, chest pain, and bleeding tendencies.

(2) If signs of bleeding, such as hematemesis, melena, or unusual bruising, occur, seek immediate medical attention.

4. Management in Special Populations

(1) Women of childbearing potential should be advised that Anagrelide may impair fertility.

(2) Breastfeeding is not recommended during treatment with Anagrelide and for one week after the last dose.